Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial

Published:2017-01 Issue:1 Volume:17 Page:58-67
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Marshall Helen S,Richmond Peter C,Beeslaar Johannes,Jiang Qin,Jansen Kathrin U,Garcés-Sánchez Maria,Martinón-Torres Federico,Szenborn Leszek,Wysocki Jacek,Eiden Joseph,Harris Shannon L,Jones Thomas R,Lee Su-San,Perez John L

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference26 articles.

1. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP);Bilukha;MMWR Recomm Rep,2005

2. A surveillance network for meningococcal disease in Europe;Trotter;FEMS Microbiol Rev,2007

3. Meningococcal disease: clinical presentation and sequelae;Pace;Vaccine,2012

4. Epidemiology and prevention of vaccine-preventable diseases,2015

5. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP);Cohn;MMWR Recomm Rep,2013

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review;Infectious Diseases and Therapy;2023-07-06

2. Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1–9 years: two phase 2 randomised, controlled, observer-blinded studies;The Lancet Infectious Diseases;2023-01

3. Meningococcal Vaccines Directed at Capsular Group B;Plotkin's Vaccines;2023

4. Proceedings of the Expert Consensus Group meeting on meningococcal serogroup B disease burden and prevention in India;Human Vaccines & Immunotherapeutics;2022-01-31

5. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults;Vaccine;2022-01